Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 412 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Tables Turned June 23, 2020 News digest – ovarian cancer blood test, statins, spending review and... October 31, 2020 FDA Approves Rituximab Plus Chemotherapy for Paediatric Cancer Indications December 10, 2021 Acing it: The ambitious early career researchers driving progress in cancer... January 21, 2022 Load more HOT NEWS FDA Approves Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable NSCLC Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... FDA Approves Crizotinib for Children and Young Adults with Relapsed or... Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies...
